Marina Frimer, MD, FACOG, FACS, associate chief, Research and Academic Development, Central Region, associate professor, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Zucker School of Medicine at Hofstra/Northwell Long Island Jewish Medical Center, Northwell Health, discusses the exploration of maintenance with niraparib (Zejula) in a phase 2 trial (NCT04080284) in patients with advanced or platinum-sensitive recurrent uterine serious carcinoma

PARP inhibitors have made a meaningful impact in the treatment of ovarian cancer, Frimer says. Uterine serous carcinoma, an aggressive type of endometrial cancer that often presents with advanced stage disease and disproportionately affects African American women, has similar genomic and clinical characteristics to ovarian serous carcinoma, Frimer adds. 

Given the similarities between the diseases and the prevalence of 

 mutations in uterine serous carcinoma, the trial aims to explore the efficacy of niraparib in this patient population, Frimer says.

This ongoing trial is actively recruiting patients, Frimer continues. The study will observe progression-free survival, overall survival, and overall response rate in patients receiving niraparib maintenance, Frimer concludes.

Videos

Marina Frimer, MD, FACOG, FACS, discusses the exploration of maintenance with niraparib in a phase 2 trial in patients with advanced or platinum-sensitive recurrent uterine serious carcinoma


Marina Frimer, MD, FACOG, FACS

Articles

Dr. Frimer on the Exploration of Maintenance with Niraparib in Uterine Serous Carcinoma